Form 4: Tyra Biosciences CEO Todd Harris Acquires 390,000 Stock Options

Tyra Biosciences' CEO, Todd Harris, was granted 390,000 stock options on August 14, 2024, according to a Form 4 filing with the SEC.

Summary

• On August 14, 2024, Todd Harris, the President and CEO of Tyra Biosciences, Inc., acquired 390,000 stock options.
• The exercise price of these options is $21.57.
• The options vest monthly, with 1/48th of the shares vesting each month following August 14, 2024, contingent upon continuous service to the Issuer.
• The options expire on August 13, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation practice. The grant itself isn't inherently positive or negative, but it does align the CEO's interests with shareholders.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant is likely determined by factors such as the CEO's performance, the company's market capitalization, and industry benchmarks for similar roles.
• Comparing the vesting schedule and exercise price to those of similar companies (e.g., Arvinas, Relay Therapeutics) would provide further context on the competitiveness of this compensation package.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with increasing shareholder value.
• Employees may see this as a sign of confidence in the company's future.

Key Dates